NCT03606967 2026-05-13Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast CancerNational Cancer Institute (NCI)Phase 2 Recruiting70 enrolled